These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
308 related articles for article (PubMed ID: 24589273)
1. Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches. Schmidt PJ; Fleming MD Hematol Oncol Clin North Am; 2014 Apr; 28(2):387-401. PubMed ID: 24589273 [TBL] [Abstract][Full Text] [Related]
2. An RNAi therapeutic targeting Tmprss6 decreases iron overload in Hfe(-/-) mice and ameliorates anemia and iron overload in murine β-thalassemia intermedia. Schmidt PJ; Toudjarska I; Sendamarai AK; Racie T; Milstein S; Bettencourt BR; Hettinger J; Bumcrot D; Fleming MD Blood; 2013 Feb; 121(7):1200-8. PubMed ID: 23223430 [TBL] [Abstract][Full Text] [Related]
3. Liver iron concentrations and urinary hepcidin in beta-thalassemia. Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680 [TBL] [Abstract][Full Text] [Related]
4. Hepcidin as a therapeutic tool to limit iron overload and improve anemia in β-thalassemic mice. Gardenghi S; Ramos P; Marongiu MF; Melchiori L; Breda L; Guy E; Muirhead K; Rao N; Roy CN; Andrews NC; Nemeth E; Follenzi A; An X; Mohandas N; Ginzburg Y; Rachmilewitz EA; Giardina PJ; Grady RW; Rivella S J Clin Invest; 2010 Dec; 120(12):4466-77. PubMed ID: 21099112 [TBL] [Abstract][Full Text] [Related]
5. SLN124, a GalNac-siRNA targeting transmembrane serine protease 6, in combination with deferiprone therapy reduces ineffective erythropoiesis and hepatic iron-overload in a mouse model of β-thalassaemia. Vadolas J; Ng GZ; Kysenius K; Crouch PJ; Dames S; Eisermann M; Nualkaew T; Vilcassim S; Schaeper U; Grigoriadis G Br J Haematol; 2021 Jul; 194(1):200-210. PubMed ID: 33942901 [TBL] [Abstract][Full Text] [Related]
6. Iron age: novel targets for iron overload. Casu C; Rivella S Hematology Am Soc Hematol Educ Program; 2014 Dec; 2014(1):216-21. PubMed ID: 25696858 [TBL] [Abstract][Full Text] [Related]
7. Hepcidin is suppressed by erythropoiesis in hemoglobin E β-thalassemia and β-thalassemia trait. Jones E; Pasricha SR; Allen A; Evans P; Fisher CA; Wray K; Premawardhena A; Bandara D; Perera A; Webster C; Sturges P; Olivieri NF; St Pierre T; Armitage AE; Porter JB; Weatherall DJ; Drakesmith H Blood; 2015 Jan; 125(5):873-80. PubMed ID: 25519750 [TBL] [Abstract][Full Text] [Related]
8. A competitive enzyme-linked immunosorbent assay specific for murine hepcidin-1: correlation with hepatic mRNA expression in established and novel models of dysregulated iron homeostasis. Gutschow P; Schmidt PJ; Han H; Ostland V; Bartnikas TB; Pettiglio MA; Herrera C; Butler JS; Nemeth E; Ganz T; Fleming MD; Westerman M Haematologica; 2015 Feb; 100(2):167-77. PubMed ID: 25425686 [TBL] [Abstract][Full Text] [Related]
9. New thiazolidinones reduce iron overload in mouse models of hereditary hemochromatosis and β-thalassemia. Liu J; Liu W; Liu Y; Miao Y; Guo Y; Song H; Wang F; Zhou H; Ganz T; Yan B; Liu S Haematologica; 2019 Sep; 104(9):1768-1781. PubMed ID: 30792208 [TBL] [Abstract][Full Text] [Related]
10. Differences in the erythropoiesis-hepcidin-iron store axis between hemoglobin H disease and β-thalassemia intermedia. Origa R; Cazzola M; Mereu E; Danjou F; Barella S; Giagu N; Galanello R; Swinkels DW Haematologica; 2015 May; 100(5):e169-71. PubMed ID: 25596269 [No Abstract] [Full Text] [Related]
11. mRNA expression of iron regulatory genes in beta-thalassemia intermedia and beta-thalassemia major mouse models. Weizer-Stern O; Adamsky K; Amariglio N; Rachmilewitz E; Breda L; Rivella S; Rechavi G Am J Hematol; 2006 Jul; 81(7):479-83. PubMed ID: 16755567 [TBL] [Abstract][Full Text] [Related]
12. Iron and hepcidin: a story of recycling and balance. Camaschella C Hematology Am Soc Hematol Educ Program; 2013; 2013():1-8. PubMed ID: 24319154 [TBL] [Abstract][Full Text] [Related]
13. Oral ferroportin inhibitor ameliorates ineffective erythropoiesis in a model of β-thalassemia. Manolova V; Nyffenegger N; Flace A; Altermatt P; Varol A; Doucerain C; Sundstrom H; Dürrenberger F J Clin Invest; 2019 Dec; 130(1):491-506. PubMed ID: 31638596 [TBL] [Abstract][Full Text] [Related]
14. β-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism. Ginzburg Y; Rivella S Blood; 2011 Oct; 118(16):4321-30. PubMed ID: 21768301 [TBL] [Abstract][Full Text] [Related]
15. Hepcidin and Hfe in iron overload in beta-thalassemia. Gardenghi S; Ramos P; Follenzi A; Rao N; Rachmilewitz EA; Giardina PJ; Grady RW; Rivella S Ann N Y Acad Sci; 2010 Aug; 1202():221-5. PubMed ID: 20712796 [TBL] [Abstract][Full Text] [Related]
16. Deletion of TMPRSS6 attenuates the phenotype in a mouse model of β-thalassemia. Nai A; Pagani A; Mandelli G; Lidonnici MR; Silvestri L; Ferrari G; Camaschella C Blood; 2012 May; 119(21):5021-9. PubMed ID: 22490684 [TBL] [Abstract][Full Text] [Related]
17. Relation of hepcidin gene expression in blood mononuclear cells with iron overload severity among β-thalassemia major patients. Ayatollahi H; Mousavi Nezhad SF; Talebpour A; Badiei Z; Nezami H Mol Biol Rep; 2020 Dec; 47(12):9353-9359. PubMed ID: 33231816 [TBL] [Abstract][Full Text] [Related]
18. Minihepcidin peptides as disease modifiers in mice affected by β-thalassemia and polycythemia vera. Casu C; Oikonomidou PR; Chen H; Nandi V; Ginzburg Y; Prasad P; Fleming RE; Shah YM; Valore EV; Nemeth E; Ganz T; MacDonald B; Rivella S Blood; 2016 Jul; 128(2):265-76. PubMed ID: 27154187 [TBL] [Abstract][Full Text] [Related]
19. Increased hepcidin in transferrin-treated thalassemic mice correlates with increased liver BMP2 expression and decreased hepatocyte ERK activation. Chen H; Choesang T; Li H; Sun S; Pham P; Bao W; Feola M; Westerman M; Li G; Follenzi A; Blanc L; Rivella S; Fleming RE; Ginzburg YZ Haematologica; 2016 Mar; 101(3):297-308. PubMed ID: 26635037 [TBL] [Abstract][Full Text] [Related]
20. Regulation of iron homeostasis by hepatocyte TfR1 requires HFE and contributes to hepcidin suppression in β-thalassemia. Xiao X; Moschetta GA; Xu Y; Fisher AL; Alfaro-Magallanes VM; Dev S; Wang CY; Babitt JL Blood; 2023 Jan; 141(4):422-432. PubMed ID: 36322932 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]